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Summary
Background.  —  Risk  assessment  is  fundamental  in  the  management  of  acute  coronary  syndromes
(ACS), enabling  estimation  of  prognosis.
Aims. —  To  evaluate  whether  the  combined  use  of  GRACE  and  CRUSADE  risk  stratiﬁcationCRUSADE schemes  in  patients  with  myocardial  infarction  outperforms  each  of  the  scores  individually
in terms  of  mortality  and  haemorrhagic  risk  prediction.
Methods.  —  Observational  retrospective  single-centre  cohort  study  including  566  consecutive
patients admitted  for  non-ST-segment  elevation  myocardial  infarction.  The  CRUSADE  model
increased GRACE  discriminatory  performance  in  predicting  all-cause  mortality,  ascertained
Abbreviations: ACS, acute coronary syndrome; AUC, area under the curve; CI, conﬁdence interval; CRUSADE, can rapid risk stratiﬁcation
of unstable angina patients suppress adverse outcomes with early implementation of the American College of Cardiology/American Heart
Association guidelines; GRACE, Global Registry of Acute Coronary Events; HR, hazard ratio; IDI, integrated discrimination improvement; NRI,
Net Reclassiﬁcation Index; NSTEMI, non-ST-elevation myocardial infarction; ROC, receiver operating characteristic.
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by  Cox  regression,  demonstrating  CRUSADE  independent  and  additive  predictive  value,  which
was sustained  throughout  follow-up.  The  cohort  was  divided  into  four  different  subgroups:
G1 (GRACE  <  141;  CRUSADE  <  41);  G2  (GRACE  <  141;  CRUSADE  ≥  41);  G3  (GRACE  ≥  141;  CRU-
SADE <  41);  G4  (GRACE  ≥  141;  CRUSADE  ≥  41).
Results.  —  Outcomes  and  variables  estimating  clinical  severity,  such  as  admission  Killip-Kimbal
class and  left  ventricular  systolic  dysfunction,  deteriorated  progressively  throughout  the  sub-
groups (G1  to  G4).  Survival  analysis  differentiated  three  risk  strata  (G1,  lowest  risk;  G2  and
G3, intermediate  risk;  G4,  highest  risk).  The  GRACE  +  CRUSADE  model  revealed  higher  progno-
stic performance  (area  under  the  curve  [AUC]  0.76)  than  GRACE  alone  (AUC  0.70)  for  mortality
prediction,  further  conﬁrmed  by  the  integrated  discrimination  improvement  index.  Moreover,
GRACE +  CRUSADE  combined  risk  assessment  seemed  to  be  valuable  in  delineating  bleeding  risk
in this  setting,  identifying  G4  as  a  very  high-risk  subgroup  (hazard  ratio  3.5;  P  <  0.001).
Conclusions.  —  Combined  risk  stratiﬁcation  with  GRACE  and  CRUSADE  scores  can  improve  the
individual  discriminatory  power  of  GRACE  and  CRUSADE  models  in  the  prediction  of  all-cause
mortality  and  bleeding.  This  combined  assessment  is  a  practical  approach  that  is  potentially
advantageous  in  treatment  decision-making.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  L’évaluation  des  risques  est  fondamentale  dans  la  gestion  des  syndromes  coronar-
iens aigus,  permettant  l’estimation  du  pronostic.
Objectifs.  —  Le  but  de  notre  étude  était  d’évaluer  l’utilisation  combinée  des  scores  GRACE  et
CRUSADE pour  la  stratiﬁcation  de  la  mortalité  et  du  risque  hémorragique  des  patients  pris  en
charge pour  un  infarctus  aigu  du  myocarde  en  comparaison  à  l’utilisation  isolée  de  chacun  de
ces scores.
Méthodes.  —  Cohorte  rétrospective  observationnelle  monocentrique  ayant  inclus  566  patients
consécutifs  hospitalisés  pour  un  syndrome  coronarien  aigu  sans  sus-décalage  du  segment  ST.
Le score  CRUSADE  a  augmenté  le  pouvoir  discriminant  du  score  GRACE  pour  la  prédiction  de
la mortalité  globale,  en  utilisant  la  régression  de  Cox,  ce  qui  démontre  la  valeur  prédictive
indépendante  et  additive  du  score  CRUSADE,  laquelle  était  maintenue  tout  au  long  du  suivi.  La
cohorte a  été  divisée  en  4  sous-groupes  :  G1  (GRACE  <  141  ;  CRUSADE  <  41)  ;  G2  (GRACE  <  141  ;
CRUSADE ≥  41)  ;  G3  (GRACE  ≥  141  ;  CRUSADE  <  41)  ;  G4  (GRACE  ≥  141  ;  CRUSADE  ≥  41).
Résultats.  — Les  événements  et  variables  qui  évaluaient  la  sévérité  clinique,  comme  la  classe
Killip-Kimbal  à  l’admission  et  la  dysfonction  systolique  du  ventricule  gauche  étaient  plus
fréquents  de  manière  linéaire  en  fonction  des  sous-groupes  (G1—G4).  L’analyse  de  la  survie
a montré  3  groupes  de  risque  (G1,  risque  bas  ;  G2  et  G3,  risque  intermédiaire  ;  G4,  risque  plus
élevé). Le  modèle  GRACE  +  CRUSADE  a  montré  une  performance  pronostique  supérieure  (AUC
0,76) au  score  GRACE  utilisé  de  manière  isolé  (AUC  0,70)  pour  la  prédiction  de  la  mortalité,
ce qui  a  été  conﬁrmé  par  l’amélioration  de  l’index  de  la  discrimination  intégrée.  De  plus,
l’évaluation  combinée  des  scores  GRACE  +  CRUSADE  semble  avoir  une  valeur  additionnelle  pour
la prédiction  de  risque  de  saignement  et  permet  d’identiﬁer  le  groupe  G4  comme  étant  à  risque
très élevé  (HR  3,5  ;  p  =  0,001).
Conclusion.  —  L’utilisation  combinée  des  scores  GRACE  et  CRUSADE  pourrait  améliorer  leur
pouvoir discriminant  en  comparaison  à  leur  utilisation  isolée  pour  la  prédiction  de  la  mor-
talité globale  ainsi  que  du  risque  hémorragique.  Cette  nouvelle  approche  semble  apporter  des
avantages  dans  la  pratique  quotidienne  et  orienter  la  prise  en  charge  thérapeutique.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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isk  assessment  is  fundamental  in  acute  coronary  syn-
rome  (ACS)  management,  enabling  estimation  of  patient
rognosis  —  a  key  issue  for  communicating  with  patients
nd  relatives,  and  for  therapeutic  decision-making.  Cur-
ent  recommendations  propose  an  aggressive  treatment
pproach  for  high-risk  non-ST-elevation  myocardial  infarc-
ion  (NSTEMI),  including  more  potent  antithrombotic
m
i
gherapies  and  a rapid  invasive  strategy  [1,2].  Conversely,
ower-risk  cases  may  do  well  with  less  aggressive  medical
reatment  and  a  more  selective  invasive  strategy.  Thus,
t  is  essential  to  assess  ischaemic  risk  on  an  individual
asis,  preferably  using  quantitative  risk  scoring  systems  such
s  the  Global  Registry  of  Acute  Coronary  Events  (GRACE)
odel  [3],  use  of  which  is  favoured  over  other  risk  scores
n  the  latest  guidelines  update  [1,2].  However,  with  the
reater  use  of  more  potent  antithrombotic  drugs  and  early
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iCRUSADE  meets  GRACE  risk  score  
revascularization,  bleeding  occurs  more  frequently  and  has
become  a  relevant  clinical  problem  in  the  ACS  setting,  mak-
ing  haemorrhagic  risk  assessment  a  necessary  tool  to  guide
treatment  strategies.  The  can  rapid  risk  stratiﬁcation  of
unstable  angina  patients  suppress  adverse  outcomes  with
early  implementation  of  the  American  College  of  Cardiol-
ogy/American  Heart  Association  guidelines  (CRUSADE)  risk
score  [4]  is  one  of  the  most  popular  bleeding  risk  algorithms,
consisting  of  several  recognized  predictors  of  haemorrhage
[5,6].  As  bleeding  results  not  only  in  an  immediate  threat  but
also  in  increased  risk  of  adverse  outcomes  during  follow-up
[7],  it  remains  to  be  determined  if  ACS  risk  assessment  with
combined  ischaemic  and  bleeding  risk  assessment  will  prove
advantageous.  Our  aim  was  to  establish  the  appropriateness
of  the  combined  use  of  GRACE  and  CRUSADE  risk  stratiﬁca-
tion  in  NSTEMI  patients  and  to  evaluate  potential  gains  in
outcome  prediction,  compared  with  the  separate  use  of  the
traditional  risk-scoring  systems.
Methods
Patient selection
This  was  an  observational  retrospective  single-centre  cohort
study  including  all  patients  consecutively  admitted  to  our
University  Hospital’s  Acute  Cardiac  Care  Unit  with  a  ﬁnal
diagnosis  of  myocardial  infarction  between  1  December  2006
and  31  May  2008.  Myocardial  infarction  was  deﬁned  accord-
ing  to  the  recently  updated  deﬁnition  [8],  excluding  patients
with  unstable  angina  and  those  with  myocardial  injury  (ele-
vated  cardiac  biomarkers)  without  evidence  of  ischaemia
(i.e.  symptoms,  electrocardiogram,  imaging  modalities).
Furthermore,  only  NSTEMI  cases  were  considered,  with  the
ﬁnal  study  cohort  including  a  total  of  566  patients.
Data collection and patient follow-up
Demographic  and  clinical  features  were  collected  at  admis-
sion  and  during  hospitalization.  The  electrocardiogram  and
analytical  assessment  (including  complete  blood  count  and
biochemical  and  clotting  tests)  were  performed  according
to  the  Acute  Cardiac  Care  Unit  standards:  at  admission
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Table  1  Cohort  distribution  according  to  GRACE  and  CRUSADE
Low-risk  class  
GRACEIH 77  (13.6)  1
GRACE6M 155  (27.3)  2
CRUSADE  222  (39.2)  1
Cross-tabulation  of  CRUSADE  and  GRACE  risk  categories
GR
Low
CRUSADE
Low-risk  class  58
Intermediate-risk  class  12
High-risk  class  6
Data are number (%). CRUSADE: in-hospital major bleeding; GRACE6M: 683
nd  then  at  least  daily,  according  to  patient’s  clinical
valuation.  Troponin  I  measurements  were  taken  at  admis-
ion,  between  12  and  24  hours  after  admission  and  daily
hereafter.  The  measurement  of  troponin  I was  performed
ith  the  chemiluminescent  technique  (Ortho  Clinical  Diag-
ostics  VITROS® Troponin  I  ES  Assay;  Johnson  &  Johnson
td.,  Maidenhead,  UK).  The  lower  detection  limit  for  this
ssay  is  0.012  ng/mL.  The  99th  percentile  upper  reference
imit  is  0.034  ng/mL,  with  a  reported  imprecision  of  10%
oefﬁcient  of  variation.  Results  >  0.034  ng/mL  were  consid-
red  positive.  Creatinine  clearance  was  estimated  using
he  modiﬁcation  of  diet  in  renal  disease  equation  [9]. The
eference  for  coronary  angiography  and  potential  percu-
aneous  myocardial  revascularization  was  an  individually
ailored  decision,  involving  the  Acute  Cardiac  Care  Unit  and
he  interventional  cardiologist’s  clinical  judgment,  in  accor-
ance  with  the  European  Society  of  Cardiology  guidelines  for
yocardial  infarction  management  [1].  Finally,  left  ventri-
ular  ejection  fraction  was  obtained  from  the  predischarge
ransthoracic  echocardiogram,  in  accordance  with  European
ssociation  of  Cardiovascular  Imaging  standards  [10].
Patients  were  followed  for  21.1  ±  7.5  months  after  dis-
harge  by  means  of  patient’s  clinical  records,  routine
isits,  consultation  of  the  National  Health  System  User  Card
atabase  and  telephone  calls  until  the  end  of  a 2-year  period
fter  discharge,  and  whenever  clinical  ﬁles  were  considered
nsufﬁcient.
isk assessment
e  tested  and  compared  the  prognostic  performance  of
RACE  [3]  and  CRUSADE  [4]  risk  stratiﬁcation  models  in  this
ohort,  through  evaluation  of  their  overall  discriminative
erformance  and  calibration  in  the  prediction  of  all-cause
ortality  during  the  index  event,  follow-up  and  in-hospital
leeding,  respectively.  The  traditional  risk  categories  of
RACE  and  CRUSADE  scores  are  depicted  in  Supplementary
able  1. The  GRACE  score  for  in-hospital  mortality  (GRACEIH)
s  more  commonly  used  in  clinical  practice  than  the  6-
onth  postdischarge  GRACE  score,  because  the  former  may
uide  revascularization  timing  in  NSTEMI  (i.e.  patients  at
igh  ischaemic  risk  [GRACE  ≥  141]  should  be  considered
or  an  early  invasive  strategy)  [1,11].  Subsequently,  the
 risk  classes.
Intermediate-risk  class  High-risk  class
35  (23.9)  354  (62.5)
19  (38.7)  192  (34.0)
26  (22.3)  218  (38.5)
ACE
-risk  class  Intermediate-risk  class  High-risk  class
 (26.1)  83  (37.4)  81  (36.5)
 (9.5)  28  (22.2)  86  (68.3)
 (2.8)  28  (12.8)  184  (84.4)
6-month postdischarge mortality; GRACEIH: in-hospital mortality.
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SADE  (for  major  bleeding)  were  tested  in  our  cohort,  and
their  discrimination  performances  are  displayed  in  Table  2.
All  scores  showed  good  calibration,  as  demonstrated  by
Hosmer—Lemeshow  test  P  values  >  0.05.
Table  2  Cohort  risk  model  performances,  using  as  con-
tinuous  variables  and  as  risk  score  categories  (low-,
intermediate-  and  high-risk  classes).
AUC  (95%  CI)  P
Continuous  variable
GRACEIH 0.81  (0.75—0.88)  <  0.001
GRACE6M 0.78  (0.73—0.83)  <  0.001
CRUSADE  0.70  (0.62—0.77)  <  0.001
Categorical  variable
GRACEIH 0.70  (0.64—0.76) <  0.001
GRACE6M 0.74  (0.69—0.83)  <  0.001
CRUSADE  0.69  (0.62—0.76)  <  0.001
GRACE  +  CRUSADEIH 0.76  (0.70—0.82)  <  0.001
GRACE  +  CRUSADE6M 0.78  (0.73—0.83)  <  0.001
GRACE  +  CRUSADEbleed 0.66  (0.59—0.74)  <  0.001
AUC: area under the curve; CI: conﬁdence interval; CRUSADE:
in-hospital major bleeding; GRACE6M: 6-month postdischarge
mortality; GRACE : in-hospital mortality; GRACE + CRUSADE :84  
ohort  was  divided  into  four  different  groups  according
o  the  presence  of  at  least  one  high-risk  category  (using
n-hospital  GRACE  and  CRUSADE  cut-offs  used  in  clinical
ractice)  [1,2]:  group  1  (G1:  GRACE  <  141  non-high-risk  class;
RUSADE  <  41  non-high-risk  class),  group  2  (G2:  GRACE  < 141,
on-high-risk  class;  CRUSADE  ≥  41,  high-risk  class);  group
 (G3:  GRACE  ≥  141,  high-risk  class;  CRUSADE  <  41,  non-
igh-risk  class);  group  4  (G4:  GRACE  ≥  141,  high-risk  class;
RUSADE  ≥  41,  high-risk  class).  Each  group  was  evaluated  in
erms  of  baseline  characteristics  and  study  endpoints.
In  this  study,  major  bleeding  was  deﬁned  in  accordance
ith  the  CRUSADE  investigators  [4]:  intracranial  hae-
orrhage,  documented  retroperitoneal  bleed,  haematocrit
rop  ≥  12%  (from  baseline),  any  red  blood  cell  transfusion
hen  baseline  haematocrit  was  ≥  28%  or  any  red  blood  cell
ransfusion  when  baseline  haematocrit  was  <  28%  with  wit-
essed  bleed.
tudy endpoints
he  primary  outcome  measures  were  in-hospital  all-cause
ortality,  all-cause  mortality  during  follow-up  and  in-
ospital  major  bleeding.
tatistical analysis
tatistical  analyses  were  done  using  SPSS® software,  ver-
ion  17.0  (StataCorp  LP,  College  Station,  Texas,  USA).
hen  needed,  baseline  characteristics  were  described  with
eans  ±  standard  deviations  for  continuous  and  counts  and
roportions  for  categorical  data.  The  Kolmogorov—Smirnov
est  was  used  to  test  the  normal  distribution  of  continuous
ariables.  The  Chi2 test  and  Student’s  t  test  were  used  for
uantitative  and  nominal  comparisons  between  two  groups,
nd  non-parametric  equivalent  tests  were  used  when  appro-
riate.  Regression  estimation  techniques  were  applied  to
eplace  missing  values  whenever  the  number  of  missing  val-
es  was  negligible,  otherwise  cases  with  missing  values  were
mitted.  P  values  <  0.05  (two-sided)  were  considered  statis-
ically  signiﬁcant.
Univariate  analysis  was  performed  to  evaluate  the  poten-
ial  association  between  each  previously  deﬁned  myocardial
nfarction  group  and  the  study  endpoints.  Cox  regression
as  used  to  evaluate  the  predictive  value  of  the  CRUSADE
core  compared  with  the  GRACE  algorithm  for  follow-up
ortality.  The  analysis  of  variance  (or  equivalent  non-
arametric  test,  when  necessary)  was  used  to  determine
ifferences  among  the  predeﬁned  myocardial  infarction  sub-
roup  means.  Discrimination,  measured  in  terms  of  the  area
nder  the  receiver  operating  characteristic  (ROC)  curve
AUC),  was  performed  to  assess  the  predictive  power  of  the
RACE  score  in-hospital  (GRACEIH)  and  6  months  postdis-
harge  (GRACE6M)  for  in-hospital  and  follow-up  mortality,
espectively,  and  of  the  CRUSADE  model  for  in-hospital
ajor  bleeding.  Finally,  the  combined  GRACE  and  CRUSADE
odel  (GRACE  +  CRUSADE)  was  tested  for  in-hospital  and
ollow-up  mortalities  and  major  bleeding.  Other  measures
f  incremental  value  have  been  proposed,  which  examine
he  extent  to  which  a  model  reclassiﬁes  subjects,  such  as  the
et  reclassiﬁcation  index  (NRI)  and  the  integrated  discrim-
nation  improvement  (IDI)  [12].  The  NRI  method,  described
y  Pencina  et  al.  [13],  states  that  a  positive  and  signiﬁcantL.  Paiva  et  al.
RI  translates  a  net  overall  successful  reclassiﬁcation  of  sub-
ects  into  a  more  appropriate  risk  category.  The  IDI,  which
ay  be  seen  as  a  continuous  form  of  the  NRI,  assesses
mprovement  in  risk  discrimination  by  estimating  the  change
n  the  difference  of  the  average  of  predicted  probabili-
ies  of  an  event  between  those  with  and  without  the  event
nder  consideration  [14];  it  is  a  more  appropriate  measure
f  risk  reclassiﬁcation  when  comparing  scores  with  differ-
nt  risk  categorization  (e.g.  GRACE  stratiﬁes  patients  into
hree  risk  strata  and  GRACE  +  CRUSADE  stratiﬁes  patients
nto  four  risk  categories).  Calibration  of  each  score  was
lso  assessed  using  the  Hosmer—Lemeshow  test.  Finally,
aplan—Meier  curves  were  constructed  to  evaluate  survival
uring  follow-up  according  to  each  predeﬁned  myocardial
nfarction  group.
esults
ohort characteristics
he  cohort  included  566  patients  with  a  mean  age  of
0.4  ±  12.3  years  (range  31—92  years),  61.3%  of  whom  were
en.  Patients’  baseline  clinical,  analytical  and  imaging
haracteristics  are  shown  in  Supplementary  Table  1.  The
ohort  distribution  according  to  GRACE  and  CRUSADE  risk
alues/categories  are  given  in  Table  1.  In  270  (47.7%)  cases
here  was  overall  concordance  between  GRACEIH and  CRU-
ADE  risk  categories;  184  (32.5%)  patients  were  classiﬁed  as
igh-risk  by  both  GRACE  and  CRUSADE  risk  models  (Table  1).
isk score performance
he  discrimination  performances  of  GRACEIH (for  in-hospital
ortality),  GRACE6M (for  follow-up  mortality)  and  CRU-IH 6M
follow-up mortality; GRACE + CRUSADEbleed: in-hospital major
bleeding; GRACE + CRUSADEIH: in-hospital mortality.
CRUSADE  meets  GRACE  risk  score  685
Table  3  Cohort  subgroup  analysis.
Subgroups  P
G1  (GRACE  <  141;
CRUSADE  <  41)
G2  (GRACE  <  141;
CRUSADE  ≥  41)
G3  (GRACE  ≥  141;
CRUSADE  <  41)
G4 (GRACE  ≥  141;
CRUSADE  ≥  41)
(n  =  173;  30.6%)  (n  =  53;  9.4%)  (n  =  168;  29.6%)  (n  =  172;  30.4%)
Age  (years) 59.7  ±  11.1 69.2  ±  9.7 74.3  ±  8.6 78.3  ±  8.3 <  0.001
Men  139  (80.3)  15  (28.3)  119  (70.8)  74  (43.0)  <  0.001
Killip-Kimball  class
(admission)
1.0 ±  0.4  1.1  ±  0.7  1.2  ±  0.7  1.8  ±  0.9  <  0.001
Systolic  arterial  pressure
(mm  Hg)
140.9  ±  23.8  148.4  ±  34.1  127.9  ±  20.0  128.0  ±  27.0  <  0.001
Heart  rate  (bpm)  72.8  ±  15.4  76.5  ±  17.0  75.9  ±  16.7  84.6  ±  22.7  <  0.001
Haemoglobin  (g/dL)  14.6  ±  1.6  12.2  ±  1.5  13.5  ±  1.7  11.9  ±  1.9  <  0.001
Haematocrit  (%)  43.8  ±  4.7  36.6  ±  4.7  40.4  ±  5.0  35.7  ±  5.9  <  0.001
Glycaemia  (mmol/L)  7.4  ±  3.6  8.6  ±  5.1  8.1  ±  3.8  10.5  ±  5.5  <  0.001
Haemoglobin  A1c  (%)  6.2  ±  1.3  6.3  ±  1.6  6.4  ±  1.3  7.1  ±  1.8  <  0.001
Serum  creatinine  (mol/L)  83.6  ±  20.0  168.8  ±  167.4  89.9  ±  28.9  204.1  ±  174.8  <  0.001
Creatinine  clearancea
(mL/min)
78.5 ±  26.2  43.6  ±  22.9  68.0  ±  25.9  45.4  ±  26.7  <  0.001
Maximum  troponin  I
(ng/mL)
12.9  ±  20.5 16.7  ±  34.5  20.9  ±  25.6  25.2  ±  46.1  0.006
NT-proBNP  (pg/mL) 857.3  ±  1131.9 3173.9  ±  3497.9 3382.3  ±  3745.2  19785.8  ±  26710.7  <  0.001
GRACE  score < 0.001
Inhospital  111.6  ±  21.1 127.4  ±  17.0 166.9  ±  21.0 195.7  ±  31.6 <  0.001
6-month  92.7  ±  19.2  110.9  ±  15.6  138.0  ±  17.1  161.91  ±  23.2
CRUSADE  score  27.9  ±  12.9  49.0  ±  9.5  32.73  ±  9.8  50.9  ±  14.5  <  0.001
LVEF  < 40%b [3,4]  10  (5.8)  8  (15.1)  35  (20.8)  61  (35.5)  <  0.001
Myocardial
revascularization
96  (55.5)  25  (47.2)  75  (44.6)  46  (26.7)  <  0.001
Percutaneous  coronary
revascularization
83 (48.0)  21  (39.6)  69  (41.1)  39  (22.7)  <  0.001
Surgical  coronary
revascularization
13 (7.5)  4  (7.5)  6  (3.6)  7  (4.1)  0.062
Three-vessel  coronary
disease
14 (8.1)  4  (7.5)  13  (7.7)  24  (13.9)  0.061
Inhospital  mortality  0  (0)  2  (3.8)  11  (6.5)  24  (14.0)  <  0.001
Follow-up  mortality  5  (3.4)  7  (13.2)  25  (14.9)  64  (37.2)  <  0.001
Major  bleeding  5  (2.9)  8  (15.1)  8  (4.8)  31  (18.0)  <  0.001
Reinfarction  12  (6.9)  6  (11.3)  23  (13.7)  35  (20.3)  <  0.001
Heart  failure
hospitalization
18 (10.4)  8  (15.1)  29  (17.3)  57  (33.1)  <  0.001
Data are number (%) or mean ± standard deviation. bpm: beats per minute; LVEF: left ventricular ejection fraction; NT-proBNP: N-terminal
pro-brain natriuretic peptide.
a Clearance of creatinine as per the modiﬁed diet in renal disease equation.
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Sb Predischarge transthoracic echocardiogram.
Study endpoint analysis
The  in-hospital  mortality  rate  was  6.7%  (n  =  38)  and  19.5%
of  patients  (n  =  103)  died  during  follow-up.  Patients  who
reached  the  primary  endpoints  were  older  and  had  sev-
eral  worse  clinical  and  analytical  ﬁndings,  and  higher  GRACE
and  CRUSADE  scores  (Supplementary  Table  2).  Predictors  of
death  in  the  univariate  analysis  are  shown  in  Supplementary
Table  3,  showing  myocardial  revascularization  (either  per-
cutaneous  or  surgical),  which  was  associated  with  a  lower
risk  of  in-hospital  mortality  (hazard  ratio  [HR]  0.20,  95%
conﬁdence  interval  [CI]  0.11—0.34;  P  <  0.001)  and  follow-up
T
a
t
sortality  (HR  0.24,  95%  CI  0.14—0.41;  P  <  0.001).  Moreover,
ajor  bleeding  was  also  related  to  follow-up  mortality  (HR
.27,  95%  CI  1.16—4.44;  P  =  0.015).  In-hospital  major  bleed-
ng  occurred  in  52  (9.2%)  patients.
ubgroup analysishe  cohort  was  divided  into  four  different  subgroups,
ccording  to  GRACE  and/or  CRUSADE  high-risk  categoriza-
ion.  Each  group’s  baseline  characteristics  and  outcomes  are
hown  in  Table  3.
6 L.  Paiva  et  al.
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The  subgroups  G1,  G3  and  G4  each  included  a  sim-
lar  number  of  cases.  Patients’  average  age,  admission
illip-Kimbal  class  and  left  ventricular  systolic  dysfunc-
ion  increased  across  the  four  groups,  with  G3  (high-risk
RACE/low-risk  CRUSADE)  and  G4  (high-risk  GRACE/high-
isk  CRUSADE)  showing  the  highest  values.  Admission  systolic
lood  pressure  was  reduced  and  peak  troponin  I and  N-
erminal  pro-brain  natriuretic  peptide  values  were  higher
n  the  groups  with  GRACE  ≥  141  (G3  and  G4).
In  those  groups  with  higher  CRUSADE  scores,  such  as  G2
low-risk  GRACE/high-risk  CRUSADE)  and  G4,  patients  had
ower  haemoglobin  and  haematocrit  and  higher  creatinine
nd  admission  glycaemia  values.
The  lowest-risk  patients  (G1)  (low-risk  GRACE/low-risk
RUSADE)  were  signiﬁcantly  more  often  revascularized  than
atients  in  higher-risk  groups,  especially  compared  with
4  (highest-risk  group).  In  terms  of  revascularization  strat-
gy,  the  proportion  of  patients  referred  for  percutaneous
oronary  intervention  or  surgery  was  balanced  between
roups  (Table  3).  Complex  coronary  disease  (three-vessel
isease)  was  more  frequent  in  G4  and,  simultaneously,  fewer
evascularization  options  (percutaneous  or  surgical)  were
onsidered  suitable  for  the  highest-risk  group  (G4).  Follow-
p  reinfarction  and  heart  failure  hospitalization  increasingly
ccurred  throughout  the  risk  subgroups  (G1  to  G4),  with  G4
howing  the  highest  rates.
Overall,  the  subgroup  analysis  allowed  the  identiﬁca-
ion  of  a  low-risk  class  (G1)  and  a  high-risk  class  (G4)
lus  two  intermediate-risk  classes  (G2  and  G3).  Although
1  and  G2  included  patients  with  GRACE  <  141,  G2  (CRU-
ADE  ≥  41)  patients  had  a  poorer  outcome  than  those  in
1  (CRUSADE  <  41).  Moreover,  while  both  G3  and  G4  com-
rised  patients  with  GRACE  ≥  141,  G4  (CRUSADE  ≥  41)  had
he  worst  prognosis.
ubgroup mortality analysis
eaths  in-hospital  and  during  follow-up  occurred  more  fre-
uently  in  groups  with  high-risk  GRACE  values  (≥  141;  G3
nd  G4).  However,  death  was  more  commonly  observed  in
2  (GRACE  <  141,  CRUSADE  ≥  41)  than  in  the  lowest-risk  cat-
gory  (G1).
The  Kaplan—Meier  analysis  is  shown  in  Fig.  1.  The  survival
urve  of  G1  (low  risk)  separates  early  from  the  other  sub-
roup  curves.  The  G2  and  G3  (intermediate  risk)  curves  were
imilar  during  the  average  follow-up,  displaying  a  much  bet-
er  survival  course  than  those  patients  classiﬁed  in  G4  (high
isk).  Differences  in  survival  between  groups  were  sustained
nd  cumulative  throughout  follow-up.
As  previously  mentioned,  revascularization  was  asso-
iated  with  higher  follow-up  and  in-hospital  survival.  In
he  subgroup  analysis,  revascularization  impacted  on  sur-
ival  only  in  the  groups  with  GRACE  >  140:  G3  (in-hospital
ortality,  HR  0.23,  95%  CI  0.03—2.07,  P  =  0.15;  follow-
p  mortality,  HR  0.20,  95%  CI  0.07—0.59,  P  =  0.002);  and
4  (in-hospital  mortality,  HR  0.42,  95%  CI  0.11—0.63,
 =  0.003;  follow-up  mortality,  HR  0.35,  95%  CI  0.16—0.75,
 =  0.006).
The  time-to-event  model  (Cox  regression)  revealed  that
he  prognostic  value  of  the  CRUSADE  score  (HR  1.03,  95%  CI
.01—1.04;  P  <  0.001)  was  independent  and  additive  to  that
e
(
(
aigure 1. Survival analysis according to predeﬁned subgroups.
f  the  GRACE6M score  (HR  1.02,  95%  CI  1.01—1.03;  P  <  0.001)
or  the  prediction  of  mortality  during  follow-up.
The  ROC  curve  comparison  (Table  2)  between  GRACE
low-,  intermediate-  and  high-risk  categories),  CRU-
ADE  (low-,  intermediate-  and  high-risk  categories)  and
RACE  +  CRUSADE  combined  (G1,  G2,  G3  and  G4)  showed
hat  the  combination  had  higher  discriminatory  performance
or  in-hospital  and  follow-up  mortality  prediction,  although
ifferences  were  not  statistically  signiﬁcant  (P  >  0.05).
owever,  IDI  (Table  4) conﬁrmed  that  GRACE  +  CRUSADE
mproved  risk  reclassiﬁcation  for  both  in-hospital  and
ollow-up  mortalities  (GRACE  +  CRUSADEIH,  relative  IDI
7.1%;  GRACE  +  CRUSADE6M, relative  IDI  11.5%).
ubgroup bleeding analysis
ajor  bleeding  rate  was  increased  in  the  subgroups  with  a
igh-risk  CRUSADE  category  (G2,  G4).  In  the  groups  with  a
ow-risk  CRUSADE  score  (G1  and  G3),  bleeding  was  signiﬁ-
antly  more  frequent  in  patients  with  GRACE  ≥  141  (G3)  than
n  patients  with  GRACE  <  141  (G1).  Moreover,  major  bleeding
isk  was  4.5  times  lower  in  G1  than  in  the  other  subgroups
HR  [G2—G4]  4.5,  95%  CI  1.8—11.7;  P  =  0.001),  establish-
ng  G1  as  a  very  low  bleeding  risk.  Additionally,  patients
n  G4  had  a  very  high  risk  of  major  bleeding  (HR  3.5,  95%
I  2.0—6.3;  P  <  0.001)  compared  with  the  remaining  sub-
roups,  including  G2,  which  already  comprised  patients  with
RUSADE  >  41  (high  bleeding  risk).
iscussion
he  combined  risk  assessment  with  GRACE  and  CRUSADE
odels  improved  the  overall  risk  stratiﬁcation  provided  by
ach  score  individually  in  the  NSTEMI  setting.  This  combined
valuation  enabled  the  distinction  of  a very—low-risk  group
GRACE  <  141,  CRUSADE  <  41)  and  a  very—high-risk  group
GRACE  ≥  141,  CRUSADE  ≥  41)  from  the  other  cases  with
n  intermediate-risk  pattern  (presence  of  either  GRACE  or
CRUSADE  meets  GRACE  risk  score  687
Table  4  Integrated  discrimination  improvement  comparing  GRACE  +  CRUSADE  model  with  GRACE  and  CRUSADE  risk
categories.
GRACE  +  CRUSADEIH GRACEIH GRACE  +  CRUSADE6M GRACE6M
Average  of  estimated
probabilities  of  an  event
0.119  0.103  0.350  0.327
Average  of  estimated
probabilities  of  a
non-event
0.064  0.065  0.173  0.181
Cross-tabulation  for  IDI  and
relative  IDI  calculation
GRACE  +  CRUSADE  IDI,  0.017;  relative  IDI,  17.07%  IDI,  0.031;  relative  IDI,  11.45%
GRACE6M: 6-month postdischarge mortality; GRACEIH: in-hospital mortality; GRACE + CRUSADE6M: follow-up mortality;
GRACE + CRUSADE : in-hospital mortality; IDI: integrated discrimination improvement.
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CRUSADE  high-risk  classes).  CRUSADE  signiﬁcantly  enhanced
the  prognostic  performance  of  the  GRACE  score.
There  is  considerable  variability  in  patient  characteris-
tics  and  outcomes  across  the  ACS  spectrum,  and  a  systematic
assessment  of  the  probability  of  adverse  events  by  quanti-
tative  risk  models  can  help  to  guide  treatment  strategies.
Although  several  ACS  risk  prediction  tools  have  been  pro-
posed  in  recent  years,  the  most  robust  ones  for  evaluating
ischaemic  and  bleeding  risk  are  the  GRACE  and  CRUSADE
scores,  respectively  [1,2].  These  risk  algorithms  are  rec-
ommended  by  contemporary  guidelines  and  have  been
incorporated  into  clinical  practice  with  potential  improve-
ments  in  decision-making.  However,  some  concerns  have
also  been  raised  concerning  the  ‘treatment—risk’  paradox
in  current  international  practice  [14],  in  which  higher-risk
patients  are  less  likely  to  receive  more  aggressive  treat-
ment  than  lower-risk  cases.  Notwithstanding,  the  early
versus  delayed  timing  of  intervention  in  patients  with  acute
coronary  syndromes  (TIMACS)  trial  [11,15]  showed  early
coronary  angiography  to  be  advantageous  in  patients  with
GRACE  >  140,  similar  to  what  was  observed  for  ST-segment
elevation  myocardial  infarction  in  each  GRACE  category
[16].  However,  there  are  no  other  studies  evaluating  the
impact  of  ACS  risk  scores  in  other  treatment  modalities,  such
as  antithrombotic  or  anticoagulation  therapies.
Major  bleeding  is  one  of  the  most  common  serious
adverse  events  in  patients  admitted  with  an  ACS  [4].  In
this  clinical  setting,  there  is  a  strong  relationship  between
bleeding  and  mortality,  even  when  the  haemorrhage  is  not
considered  to  be  severe.  Major  bleeding  is  associated  with
a  60%  increase  in  hospital  death  [17]  and  a  ﬁvefold  increase
in  1-year  mortality  [7].  The  bleeding-mortality  interaction
seems  to  be  attributable  to  more  than  the  speciﬁc  bleeding
episode.  A  signiﬁcant  haemorrhage  may  lead  to  complete
cessation  of  antithrombotic  therapy  and  potential  ischaemic
recurrences.  Moreover,  the  advancing  ACS  therapies  are
increasingly  offered  to  higher-risk  patients  (e.g.  the  elderly,
those  with  co-morbidities)  who  also  have  an  increased  risk
of  bleeding  complications.  Therefore,  ACS  risk  stratiﬁcation
needs  to  be  reliable  in  outlining  the  patient’s  risk  proﬁle.  We
believe  that  ischaemic  and  bleeding  risks  should  be  eval-
uated  simultaneously.  Bleeding  has  an  impact  beyond  the
index  event  and  ACS  management  is  much  more  than  total
ischaemic  burden.  Besides,  ischaemia  and  bleeding  share
t
c
r
wverlapping  risk  factors  (e.g.  older  age,  diabetes,  renal  dys-
unction),  and  it  is  not  uncommon  to  ﬁnd  an  ACS  patient  who
s  at  high  risk  of  death/ischaemic  recurrences  and  is  simulta-
eously  at  increased  risk  of  dismal  bleeding  complications.
n  our  cohort,  we  found  concordance  between  GRACE  and
RUSADE  risk  categories  in  approximately  50%  of  cases,  with
early  one-third  of  patients  presenting  concurrent  GRACE
nd  CRUSADE  high-risk  categories.  Patient  management  in
hese  cases  is  challenging  and  we  ought  to  understand  more
bout  ACS  risk  proﬁles  and  related  outcomes.
We  assessed  the  strength  of  the  combined  evalua-
ion  by  GRACE  and  CRUSADE  models  using  a cut-off
GRACE  ≥  141)  related  to  the  optimal  revascularization
iming  in  NSTEMI  and  the  high-risk  bleeding  category  (CRU-
ADE  ≥  41).  Through  these  division  criteria,  which  are  easily
btainable,  we  sought  to  deﬁne  four  different  NSTEMI
isk  proﬁles:  low  ischaemic  and  bleeding  risk  patients
GRACE  < 141;  CRUSADE  <  41);  high  ischaemic  and  bleeding
isk  cases  (GRACE  ≥  141;  CRUSADE  ≥  41);  and  to  identify  sig-
iﬁcant  differences  between  the  intermediate-risk  proﬁles
GRACE  < 141;  CRUSADE  ≥  41/GRACE  ≥  141;  CRUSADE  <  41)
nd  the  former  subgroups.  Our  results  suggest  that  these
ubgroups  are  very  different  from  each  other  in  terms
f  patient  characteristics  and  outcomes.  Several  clinical
ariables,  such  as  admission  Killip-Kimbal  class  and  left
entricle  systolic  dysfunction,  and  outcomes  deteriorated
igniﬁcantly  throughout  the  subgroups  (G1  to  G4).  Patients
ith  GRACE  ≥  141  were  expected  to  have  a poorer  outcome.
owever,  those  with  a  GRACE  score  <  141  but  with  a high-risk
RUSADE  score  had  a  worse  prognosis  than  patients  in  the
1  group  (lowest-risk  group).  Similarly,  patients  in  G3  (high-
isk  GRACE  class)  did  not  have  a  worse  clinical  picture  than
hat  observed  in  G4  (highest-risk  group).
The  CRUSADE  model  increased  the  discriminatory  perfor-
ance  of  GRACE  in  the  prediction  of  all-cause  mortality,
scertained  by  a  time-to-event  model  (Cox  regression),
howing  CRUSADE  to  have  an  independent  and  additive
redictive  value  that  is  sustained  throughout  follow-
p.  This  improved  performance  of  the  GRACE  +  CRUSADE
odel  was  demonstrated  by  survival  curves  (Fig.  1)hat  clearly  differentiate  three  strata  (G1,  lowest-risk
urve;  G2  and  G3,  intermediate-risk  curve;  G4,  highest-
isk  curve).  The  GRACE  +  CRUSADE  prognostic  performance
as  measured  using  ROC  analysis,  establishing  a  higher
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ombined  risk  model  AUC  (GRACE  +  CRUSADEIH, AUC  0.76;
RACE  +  CRUSADE6M,  AUC  0.78)  than  GRACE  categories
GRACEIH,  AUC  0.70;  GRACE6M,  AUC  0.74)  for  both  in-hospital
nd  follow-up  mortalities,  although  the  difference  was
ot  statistically  signiﬁcant.  As  AUC  cannot  always  mea-
ure  a  clinically  meaningful  improvement  in  reclassiﬁcation,
n  extended  statistical  evaluation  with  IDI  documented  a
uccessfully  improvement  in  reclassiﬁcation,  strongly  sug-
esting  that  the  combined  risk  model  would  be  clinically
aluable.
Myocardial  revascularization  was  associated  with  follow-
p  and  in-hospital  survival  advantage.  In  the  subgroup
nalysis,  revascularization  beneﬁts  were  only  evident  in
hose  with  GRACE  >  140,  mostly  G4  (highest-risk  patients).
et,  the  higher  rate  of  revascularization  was  seen  in  the  low-
st  risk  group  (G1)  (‘treatment—risk’  paradox).  Our  results
eemed  to  indicate  that  cases  of  lower  ischaemic  risk  and
igh  bleeding  hazard  (G3)  might  be  better  managed  with  a
ore  conservative  revascularization  approach.
Another  key  section  of  this  study  was  to  assess  the
trength  of  GRACE  +  CRUSADE  in  major  bleeding  prediction
nd  to  determine  whether  the  combined  risk  assessment  is
f  greater  value  than  CRUSADE  evaluation  only.  As  expected,
2  and  G4  (CRUSADE  ≥  41)  had  a  higher  rate  of  bleed-
ng.  Notwithstanding,  the  addition  of  the  GRACE  algorithm
ade  it  possible  to  differentiate  bleeding  risk  proﬁles:  G3
ad  higher  bleeding  rates  than  G1  (although  both  had  CRU-
ADE  <  41)  and  the  G4  subgroup  had  an  increased  bleeding
azard  compared  with  G2  (Table  3).  Remarkably,  patients
n  G4  had  bleeding  risk  that  was  3.5  times  higher  than  all
emaining  groups.
Currently,  ACS  guidelines  do  not  advise  on  tailoring
edical  treatment  in  NSTEMI,  assuming  that  all  ischaemic
ases  will  derive  similar  and  potential  beneﬁt  from  sev-
ral  treatment  modalities  (i.e.  anticoagulation  and  newer
ntiplatelet  regimens),  unless  contraindicated.  Neverthe-
ess,  this  four-group  approach  may  potentially  alter  a
atient’s  usual  management  regarding  preload  doses  or
ther  treatment  options,  to  ensure  that  they  gain  most
dvantage  from  them.  In  the  future,  it  might  be  suit-
ble  to  use  a  more  conservative  management  strategy  for
atients  with  low  ischaemic  burden  (e.g.  no  preloading  dose
r  weaker  antiplatelet  regimens  [clopidogrel  versus  tica-
relor/prasugrel]).  Nevertheless,  as  previously  discussed,
2  did  not  behave  like  a  low-risk  group,  showing  a worse
schaemic  prognosis  compared  with  G1  (although  both
ad  GRACE  <  141),  and  could  possibly  beneﬁt  more  from
ntithrombotic  therapies  and  preloading.  Moreover,  con-
erning  the  groups  at  highest  ischaemic  risk  (G3  and  G4),
ne  should  focus  on  the  bleeding  risk.  G4  had  the  higher
ncidence  of  bleeding  events  as  well  as  the  worst  long-term
rognosis.  Because  bleeding  is  strongly  associated  with  mor-
ality  and  as  bleeding  events  occur  early  in  the  course  of
yocardial  infarction,  it  would  be  appropriate  to  refrain
rom  giving  preloading  doses  or  combined  antiplatelet  thera-
ies  or  stronger  anticoagulation  regimens  to  these  patients.
resently,  we  do  not  fully  understand  the  heterogeneous
roup  of  NSTEMI  or  its  best  management,  and  upcoming
CS  recommendations  need  to  address  the  possibility  of
atient-tailored  therapy,  regarding  the  speciﬁcities  of  each
isk  group  and  the  aetiological  nature  of  the  myocardial
nfarction.
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In  our  view,  this  study  increased  comprehension  of  the
CS  risk  proﬁles,  their  characteristics  and,  more  impor-
antly,  their  outcomes.  They  study  supports  the  concept
hat  ACS  patients  should  be  seen  as  a  whole  and  that
leeding  should  be  prevented  intensely  due  to  its  huge
rognostic  impact.  Importantly,  combined  assessment  with
RACE  +  CRUSADE  signiﬁcantly  improved  the  discriminatory
ower  of  both  GRACE  and  CRUSADE  when  used  separately.
ithout  new  risk  assessment  tools,  this  combined  and  prac-
ical  approach  might  be  a  step  forward  in  the  future
anagement  of  NSTEMI.
tudy limitations
his  was  a  single-centre  case-control  study,  which  was  ret-
ospective  in  nature,  with  a  small-to-moderate  sample  size.
ecause  patient  inclusion  began  in  2006,  this  study  sample
ay  not  represent  the  state  of  the  art  in  ACS  management,
s  it  has  changed  importantly  in  the  past  decade  regarding
edical  treatment  and  revascularization  procedures.  More-
ver,  the  relatively  small  number  of  patients  included  in
ome  groups  (e.g.  G2,  n  =  53)  may  have  limited  interpreta-
ion  of  results.  Nonetheless,  it  is  our  impression  that  larger
roups,  such  as  in  the  case  of  G2,  would  rather  enhance
hose  differences  found,  such  as  those  concerning  haemor-
hagic  events.  Another  limitation  of  this  study  was  the  use  of
isk  models  that  shared  overlapping  risk  variables  (e.g.  heart
ate,  systolic  blood  pressure,  Killip-Kimbal  class,  creatinine
learance  [Supplementary  Table  4]),  which  could  have  led
o  a redundant  clinical  assessment.
Although  this  study  attempts  to  improve  myocardial
nfarction  risk  stratiﬁcation  with  a  highly  practical  compo-
ent,  it  cannot  be  extrapolated  to  other  populations.  Our
esults  warrant  further  validation  in  larger  and  independent
ohorts  before  drawing  any  deﬁnite  clinical  applicability
rom  these  data.
onclusions
 combined  risk  stratiﬁcation  strategy  with  both  the  GRACE
nd  CRUSADE  models  enables  a  more  accurate  prediction
f  all-cause  mortality  and  bleeding  risk  in  patients  with
STEMI.  The  two  scores  complement  each  other  in  the
rognostication  of  these  patients,  potentially  allowing  more
ccurate  identiﬁcation  of  patients  who  will  beneﬁt  from
ore  aggressive  therapies  and  those  who  are  suited  to  a
ore  conservative  approach.
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Appendix A. Supplementary data
Supplementary  data  associated  with  this  article  can
be  found,  in  the  online  version,  at  http://dx.doi.org/
10.1016/j.acvd.2014.06.008.
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